15 Best Biotech Penny Stocks to Invest in Right Now

Page 10 of 13

4. Atai Life Sciences N.V. (NASDAQ:ATAI)

Year-to-Date Return: 272.18% 

Atai Life Sciences N.V. (NASDAQ:ATAI), headquartered in the Netherlands, is a clinical-stage biopharmaceutical company developing innovative treatments for mental health disorders, including depression, anxiety, and substance use disorders. The company leverages a data-driven platform to advance psychedelic-derived and other novel therapeutics aimed at transforming mental health care.

In September 2025, Atai Life Sciences N.V. (NASDAQ:ATAI) actively participated in major investor conferences, including the Cantor Global Healthcare and H.C. Wainwright Annual Global Investment Conferences, demonstrating strong engagement with investors. The company also strengthened its governance by appointing two independent directors, signaling a focus on long-term strategic planning.

ATAI’s stock has surged over 250% year-to-date, recently trading near a 52-week high of $4.72, supported by robust revenue growth of 163.4%. Analysts remain optimistic, with a strong buy consensus.

The business continues advancing key programs, including PCN-101, an R-ketamine derivative for treatment-resistant depression, and RL-007 for schizophrenia subpopulations.

Page 10 of 13